Mwangilwa Kelvin, Sialubanje Cephas, Chipoya Musole, Mulenga Chilufya, Mwale Moses, Chileshe Charles, Sinyange Danny, Banda Moses, Gardner Priscilla Nkonde, Lamba Lilian, Kalubula Precious, Simwanza John, Simwaba Davie, Kapata Nathan, Mwanza Jonathan, Chipimo Peter J, Mbewe Nyuma, Sinyange Nyambe, Fwemba Isaac, Kapin'a Muzala, Chilengi Roma
Zambia National Public Health Institute, Stand Number 1186 Corner of Chaholi Road and Addis Ababa, Rhodes Park, Lusaka, Zambia.
WHO Country Office, PO Box 32346, 10101, Lusaka, Zambia.
Trop Med Health. 2025 Apr 25;53(1):59. doi: 10.1186/s41182-025-00736-2.
The COVID-19 pandemic had a devastating impact on childhood routine immunization programs, resulting in increased measles mortalities and complications. In Zambia, the likelihood of measles-related deaths and complications in children was possibly increased because of high rates of unvaccinated children, late diagnosis, and poor case management, which could have been a consequence of exclusive focus on COVID-19 interventions. This study aimed at examining the effect of the COVID-19 pandemic on measles mortality and its predictors among patients seen at health facilities in Zambia.
We used longitudinal data (January 2020 to August 2023) from outbreak investigations and time series data from 2017 to 2023 to understand the impact of COVID-19 on measles immunization and know the predictors of measles mortalities. The period running from January 2017 to February 2020, just before the first reported COVID-19 case, was defined as pre-COVID-19, and March 2020 to December 2023 as post-COVID-19. Multivariable logistic regression analysis was used to determine predictors of mortality. A segmented Poisson regression model was used to determine the correlation between the underlying patterns of measles mortality and the commencement of the COVID-19 pandemic.
A total of 3429 measles cases were reported during the study period. Of these, 1261 had complete metadata and were included in the analysis. The median age was 3 years (IQR, 1-7). Out of the 1261 enrolled, 54 (4.3%) were reported died. A total of 205 (21.0%) were IgM positive, and 207 (16.9%) were vaccinated. Monthly measles mortality increased by 220%, from 0.06 per 100,000 before COVID-19 to 0.23 during the pandemic. Predictors of mortality were younger age category (0-4) (AOR = 2.78; 95% CI 1.16-7.14), testing positive for measles IgM (AOR = 2.17; 95% CI 1.07-4.39), rush (AOR = 3.66; 95% CI 1.31, 6.21), and female sex (AOR = 1.90; 95% CI 1.04-3.50), which increased the odds of dying. However, being vaccinated (AOR = 0.06; 95% CI 0.01-0.42) reduced the odds of dying. Evidence for the COVID-19 effect was strongly associated with increased measles mortality (RR, 1.02; 95% CI 1.00, 1.04; 0.017) with a trend step change of 81% (RR, 1.81; 95% CI 1.14-2.87). There was also an increased trend of measles cases (RR, 1.04; 95% CI 1.01-1.06) during the pandemic. Measles dose 2 vaccination trends increased by about 0.3% during the COVID-19 pandemic due to the Supplementary Immunization Activity (SIA) (RR, 1.003; 95% CI 1.000-1.010). However, there was a dramatic drop of about 42% (RR = 0.58, 95% CI 0.46-0.72).
Measles caused a significant increase in child mortality during the pandemic period. A mix of systemic, clinical, and individual factors affected measles mortality. Prioritizing vaccine coverage, especially for younger children and marginalized populations; enhancing diagnostic and treatment capacities; and addressing gender and healthcare access disparities are all essential components of interventions aimed at lowering mortality. The findings suggest that public health interventions focusing on measles vaccination, rapid detection, and appropriate case management are crucial to reducing mortality and preventing further transmission. To achieve population immunity, sustained efforts are required to maintain high coverage rates.
新冠疫情对儿童常规免疫规划产生了毁灭性影响,导致麻疹死亡率和并发症增加。在赞比亚,由于未接种疫苗儿童比例高、诊断延迟和病例管理不善,儿童患麻疹相关死亡和并发症的可能性可能增加,而这可能是只专注于新冠疫情干预措施的结果。本研究旨在调查新冠疫情对赞比亚医疗机构中麻疹死亡率的影响及其预测因素。
我们使用了疫情调查的纵向数据(2020年1月至2023年8月)以及2017年至2023年的时间序列数据,以了解新冠疫情对麻疹免疫的影响,并了解麻疹死亡率的预测因素。2017年1月至2020年2月(即首次报告新冠病例之前)这段时间被定义为新冠疫情前,2020年3月至2023年12月为新冠疫情后。多变量逻辑回归分析用于确定死亡率的预测因素。分段泊松回归模型用于确定麻疹死亡率的潜在模式与新冠疫情开始之间的相关性。
研究期间共报告了3429例麻疹病例。其中,1261例具有完整的元数据并纳入分析。中位年龄为3岁(四分位间距,1 - 7岁)。在纳入的1261例中,54例(4.3%)报告死亡。共有205例(21.0%)IgM呈阳性,207例(16.9%)接种过疫苗。麻疹月死亡率增加了220%,从新冠疫情前的每10万人0.06例增至疫情期间的每10万人0.23例。死亡率的预测因素包括年龄较小(0 - 4岁)(比值比 = 2.78;95%置信区间1.16 - 7.14)、麻疹IgM检测呈阳性(比值比 = 2.17;95%置信区间1.07 - 4.39)、匆忙(比值比 = 3.66;95%置信区间1.31, 6.21)以及女性(比值比 = 1.90;95%置信区间1.04 - 3.50),这些因素增加了死亡几率。然而,接种疫苗(比值比 = 0.06;95%置信区间0.01 - 0.42)降低了死亡几率。新冠疫情影响的证据与麻疹死亡率增加密切相关(相对风险,1.02;95%置信区间1.00, 1.04;P = 0.017),趋势变化为81%(相对风险,1.81;95%置信区间1.14 - 2.87)。疫情期间麻疹病例也呈上升趋势(相对风险,1.04;95%置信区间1.01 - 1.06)。由于补充免疫活动,新冠疫情期间麻疹第二剂疫苗接种趋势增加了约0.3%(相对风险,1.00
3;95%置信区间1.000 - 1.010)。然而,出现了约42%的大幅下降(相对风险 = 0.58,95%置信区间0.46 - 0
.72)。
在疫情期间,麻疹导致儿童死亡率显著上升。一系列系统、临床和个体因素影响了麻疹死亡率。优先提高疫苗接种覆盖率,特别是针对幼儿和边缘化人群;增强诊断和治疗能力;解决性别和医疗服务可及性方面的差距,都是旨在降低死亡率的干预措施的重要组成部分。研究结果表明,专注于麻疹疫苗接种、快速检测和适当病例管理的公共卫生干预措施对于降低死亡率和防止进一步传播至关重要。为实现群体免疫,需要持续努力以维持高覆盖率。